Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 27, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | pharma, top ten
Another week comes to a close, and it’s time to review the biggest stories of the week. Check out the ten most popular articles on Pharamfile.com over the past seven days below:
10. Bluebird bio’s Lenti-D gene therapy shows promise in cerebral adrenoleukodystrophy
Bluebird bio has revealed updated data for its investigational Lenti-D gene therapy in the treatment of cerebral adrenoleukodystrophy (CALD), a rare genetic and rapidly progressive disease that carries the threat of severe loss of neurologic function and death, a the 13th European Pediatric Neurology Society (EPNS) Congress in Athens.
9. Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy
Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for the treatment of locally advanced or metastatic solid tumours with an NTRK gene fusion in adult and paediatric patients who have no satisfactory treatment options, or for whom surgical resection is likely to result in severe morbidity.
8. Antidepressant sertraline works ‘by reducing anxiety symptoms first’
Researchers at University College London have found that a commonly prescribed antidepressant, sertraline, works in unexpected ways, first relieving users of anxiety and then having a smaller effect on depressive symptoms weeks later.
7. Biogen to start new Spinraza trial to preserve market share
Biogen is planning a new trial of $1.7billion-a-year Spinraza to investigate much higher doses in spinal muscular atrophy (SMA) and thwart off competition from new player Zolgensma from Novartis.
6. EMA’s CHMP recommends three new medications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) have recommended approval for three new medicines with AstraZeneca securing approval from regulators to market its Qtrilmet tablets for the treatment of type 2 diabetes.
5. NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales for the prevention of chronic and episodic migraine in adult patients who experience at least four episodes of migraine a month.
4. Iran reveals plans to domestically produce 135 strategic drugs
Iran has announced plans to promote self-sufficiency within the country with regard to its medicines production, with an aim of producing 135 strategic pharmaceutical products within its borders.
3. FDA approves Novo’s new type 2 diabetes pill
A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the use in patients with type 2 diabetes to lower blood sugar levels.
2. Lundbeck and Takeda’s depression drug approved in Japan
Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug Trintellix (vortioxetine) for the treatment of major depressive disorder, described in the companies’ press release as “depression and depressed state”.
1. Servier on trial for weight-loss pill that led to 2,000 deaths
A trial on one of France’s largest ever healthcare scandals has begun after a weight loss pill was believed to have killed up to 2,000 people, leaving many more injured for life.
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …
